Core Viewpoint - Dizh Medical (688192) announced that its two innovative products, DZD8586 and DZD6008, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, highlighting the company's competitive advantages in the fields of hematological malignancies and lung cancer [1] Group 1: DZD8586 in B-NHL and CLL/SLL - DZD8586 is expected to provide a new treatment option for patients with B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - A summary analysis of a Phase I/II clinical study involving 51 patients with relapsed/refractory CLL/SLL showed an objective response rate (ORR) of 84.2% at a recommended dose of 50mg, indicating good anti-tumor efficacy and manageable safety [2] - DZD8586 also demonstrated anti-tumor activity in a Phase II study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with promising results to be presented at the 2025 European Hematology Association (EHA) annual meeting [2][3] Group 2: DZD6008 in NSCLC - DZD6008 is anticipated to address unmet clinical needs in non-small cell lung cancer (NSCLC), particularly for patients with EGFR mutations who have undergone multiple lines of treatment [4] - Early clinical data from the TIAN-SHAN2 study showed that 83.3% of 12 patients with advanced NSCLC experienced tumor shrinkage after treatment with DZD6008, demonstrating durable anti-tumor activity and good tolerability [4][5] - DZD6008 exhibits excellent blood-brain barrier penetration, with a concentration ratio in cerebrospinal fluid exceeding 1, indicating its potential effectiveness in patients with brain metastases [4][5] Group 3: Company Strategy and Future Outlook - The founder and CEO of Dizh Medical emphasized the company's commitment to accelerating the global development of DZD8586 and DZD6008, aiming to provide more treatment options for patients with B-NHL and NSCLC [6] - The promising clinical data presented at ASCO reinforces the company's confidence in advancing DZD8586 into Phase III clinical trials [6]

2025.05. 24 本文字数：2099，阅读时长大约3分钟 Wind数据显示，在已经披露2024年年报的药企中，高管年薪在千万以上绝非个例。在俞德超之前， 还有多家药企的高管薪酬过亿。 作者 | 第一财经 陈敏之 近日，理想汽车（02015.HK/LI.US）创始人、董事长兼CEO李想2024年领取6.39亿元"天价年薪"冲 上热搜引发热议。 事实上，创新药企业里，也不乏上亿年薪的创始人和CEO，但有所不同的是，这些创新药公司多数 还没有走完商业化历程，公司处于连年亏损状态。比如刚刚敲钟上市的映恩生物（9606.HK），创 始人朱忠远去年薪酬8556万元，公司同期亏损超过10亿元。近期三次递表港交所的英矽智能，执行 董事任峰2024年薪酬总计307.3万美元，公司当年净亏损1709.6万美元。 这样例子在创新药企业里比比皆是。Wind数据显示，思路迪医药股份（1244.HK）董事长龚兆龙 2024年的薪酬为2067万元，六年的薪酬总额则超过5亿元，而公司六年亏损超40亿元。 高薪背后，是创新药行业整体尚未步出资本寒冬。高管的收入与公司业绩形成的强烈反差，引发市场 对行业价值导向的深度思考。 年薪千万比比皆 ...

Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]

Core Insights - DIZHE Pharmaceutical announced the presentation of two innovative drugs, DZD8586 and DZD6008, at the 2025 ASCO annual meeting, focusing on their advancements in treating B-cell non-Hodgkin lymphoma (B-NHL) and non-small cell lung cancer (NSCLC) [1][2] Group 1: DZD8586 - DZD8586 is a first-in-class, non-covalent dual-target inhibitor of LYN/BTK that can fully penetrate the blood-brain barrier [1] - In a study involving 51 patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DZD8586 demonstrated an objective response rate (ORR) of 84.2% at a 50mg dosage, with 78.9% of patients continuing treatment [1] - Another study on DZD8586 for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) showed good anti-tumor activity and safety at both 50mg and 75mg dosages [2] Group 2: DZD6008 - DZD6008 is a novel, highly selective EGFR tyrosine kinase inhibitor (TKI) that also fully penetrates the blood-brain barrier [2] - In a study of 12 advanced NSCLC patients with various EGFR mutation types, DZD6008 exhibited encouraging and durable anti-tumor activity with good tolerability [2] - The ongoing research aims to further validate the efficacy and safety of DZD6008 in a broader population, potentially enhancing treatment options for advanced lung cancer patients [2] Group 3: Company Strategy and Future Plans - The CEO of DIZHE Pharmaceutical expressed confidence in advancing DZD8586 to Phase III clinical trials, highlighting its significant efficacy in treating CLL/SLL [2] - The company aims to accelerate the global development of both DZD8586 and DZD6008, seeking to provide more treatment options for patients with B-NHL and NSCLC [2]

Group 1 - Public funds have actively participated in the A-share private placement market, with a total allocation amount of 9.785 billion yuan and a floating profit of 1.694 billion yuan, resulting in an overall floating profit ratio of 17.32% as of May 20, 2025 [1][3] - The top-performing public fund is Yimi Fund, achieving a floating profit ratio of 49.49% with a floating profit of 39.588 million yuan from an allocation of 80 million yuan [1][3] - Companies like Leshan Power and Sheng Tai Co. have shown significant floating profits, with Leshan Power leading at a floating profit ratio of 178% [3][4] Group 2 - Private funds have also shown strong performance, with 27 private institutions participating in 23 A-share companies, achieving a total allocation of 1.943 billion yuan and a floating profit of 528 million yuan, resulting in a floating profit ratio of 27.19% as of May 21, 2025 [2][6] - Small-scale private funds have excelled, with Lihua Investment achieving a floating profit ratio of 178.04% from a single allocation of 810,000 yuan [7][8] - The overall performance of the private placement market indicates a trend towards higher returns in sectors such as new energy, semiconductors, and high-end manufacturing, which account for over 70% of the high floating profit ratios [9]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-33 迪哲（江苏）医药股份有限公司 自愿披露关于 DZD8586 和 DZD6008 最新研究成果在 2025 年美国临床肿瘤学会（ASCO）年会上公布的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）宣布，其自主研发的 两款源头创新药物DZD8586和DZD6008将于2025年美国临床肿瘤学会（ASCO） 年会上，分别报告在 B 细胞非霍奇金淋巴瘤（B-NHL）和非小细胞肺癌（NSCLC） 领域的三项最新研究进展。这进一步彰显了公司在血液肿瘤与肺癌领域全球差异 化竞争的新优势。其中，DZD8586 治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 （CLL/SLL）的汇总分析结果将以口头报告形式公布。 一、关于 DZD8586 相关研究 DZD8586 是一款全球首创、可完全穿透血脑屏障的非共价 LYN/BTK 双靶 点抑制剂。DZD8586 针对既往接受过重度治疗的 CLL/SLL 患者的一项 I/II 期临 ...

Core Viewpoint - Recent announcements from Dize Pharmaceutical indicate significant insider selling, with the chairman and two vice presidents reducing their stakes in the company due to personal financial needs [1][6]. Insider Selling - On May 19, Dize Pharmaceutical announced that Vice President and Chief Commercial Officer Wu Qingyi plans to sell up to 302,054 shares, representing no more than 0.0657% of the total share capital, while Vice President Zhang Shiying intends to sell up to 16,000 shares, accounting for no more than 0.0035% of the total share capital [1][2]. - The selling period is set from June 24, 2025, to September 23, 2025, with prices determined by market conditions during the selling period [1]. Shareholding Information - As of the announcement date, Wu Qingyi holds 1,208,217 shares, which is 0.2630% of the total share capital, while Zhang Shiying holds 65,000 shares, or 0.0141% of the total share capital [2]. Market Performance - As of May 20, Dize Pharmaceutical's stock price increased by 1.91%, closing at ¥57.53, with a total market capitalization of ¥26.43 billion [3][4]. - The estimated total value of the shares to be sold by the two vice presidents is approximately ¥18.29 million [3]. Company Background - Dize Pharmaceutical was established on October 27, 2017, with a registered capital of ¥416 million, focusing on the research and wholesale of chemical drugs and biological medicines [7]. - The major shareholder is AstraZeneca AB, holding 26.21% of the company [7]. Financial Performance - In 2024, Dize Pharmaceutical reported revenues of ¥360 million, a year-on-year increase of 294.24%, but incurred a net loss of approximately ¥846 million, compared to a loss of ¥1.108 billion in the previous year [7]. - For the first quarter of 2025, the company achieved revenues of ¥160 million, a 96.32% year-on-year increase, with a net loss of approximately ¥193 million, compared to a loss of ¥224 million in the same period last year [7].

申万宏源研究指出，受2024年9月以来市场情绪好转以及2025年2月科技、AI等题材催化，行业及个股 表现自2024年三季度起修复，2024年四季度起解禁绝对收益回暖。在此背景下，2025一季度上市的竞价 定增项目行业及个股估值升至相对高位，但上市节奏较慢，项目"稀缺性"叠加投资者参与度升温，导致 定增发行价格相较于二级市场的折扣有所收窄。目前，过会及注册节奏环比加快、存量项目数已达到近 期高位。展望2025二季度，预期定增发行将维持稳中有增的趋势，受投资者对定增项目需求增加的影 响，基准折价率预计将维持10%左右。 具体来看，在公募机构参与定增的股票中，昊华科技（600378）最受公募机构定增青睐，共有财通基 金、大成基金和诺德基金3家公募机构参与到该股定增，合计获配金额达16.28亿元。另外，国联民生 （601456）、迪哲医药(688192)、安宁股份（002978）、中钨高新（000657）、佰维存储(688525)和中 远海特（600428）等6股定增同样受到公募机构青睐，获配金额均超5亿元。 值得一提的是，在市场行情持续平稳震荡的情况下，多数公募机构参与定增实现浮盈。以5月19日收盘 价计算，年内 ...

2. 百纳千成(300291.SZ)：股东刘德宏计划在15个交易日后的3个月内通过集中竞价及大宗交易方式减持 不超过9,418,896股，占公司总股本的1%。 3. 北京君正(300223.SZ)：股东、董事张紧通过集中竞价交易方式减持600,000股，占公司总股本的 0.1246%，减持计划已实施完毕。 4. 倍杰特(300774.SZ)：控股股东、实际控制人权秋红通过集中竞价方式累计减持1,815,500股，占公司 总股本的0.44%，持股比例降至42.94%。 5. 博亚精工(300971.SZ)：董事周继红及监事会主席陈思立的减持计划时间届满，周继红减持8,400股， 陈思立减持247,200股。 6. 博众精工(688097.SH)：股东苏州众二及董事蒋健、宋怀良、马金勇提前终止减持计划，苏州众二减 持9,306,425股，蒋健减持22,443股，宋怀良减持32,750股，马金勇未减持。 1. ST路通(300555.SZ)：高级管理人员庄小正计划在15个交易日后的3个月内通过集中竞价交易方式减持 不超过671,700股，占公司总股本的0.34%。 7. 朝阳科技(002981.SZ)：控股股东一致 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-32 迪哲（江苏）医药股份有限公司 公司于近日收到吴清漪女士、张世英（CHANG SHIH-YING）博士（以下简 称"减持主体"）相关股份减持计划的告知函，现将有关情况公告如下： | 一、减持主体的基本情况 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 吴清漪 | | | | | | | | | | 控股股东、实控人及一致行动人 | | | | | | | □是 | √否 | | 直接持股 | 5%以上股东 | | | | | □是 | √否 | | | 股东身份 | | | | | | | | | | 董事、监事和高级管理人员 | | | | | | | √是 | □否 | | 其他：无 | | | | | | | | | | 持股数量 1,208,217股 | | | | | | | | | | 持股比例 0.2630% | | | | | | | | | | 股权激励取得：1,196,417股 | | | | | | | | ...